CEO Henrik Nittmar commentsn“ During the second quarter of the year, Corline strengthened the image of a company in the process of creating two very attractive value-creating business lines. The combination of the medical technology segment, which means previous revenues with very good profitability, and drug development in the form of Renaparin, gives the company a good risk balance while we maintain and develop the great potential in the technology platform ”